#

Eli Lilly

: 82
Eli Lilly has disappointed with the outcome of a weight loss pill trial. Shares are down 15%
News·
Eli Lilly has disappointed with the outcome of a weight loss pill trial. Shares are down 15%
The Novo Nordisk case: how the creator of Ozempic lost leadership in the market it created
Review·
The Novo Nordisk case: how the creator of Ozempic lost leadership in the market it created
Morning in New York: foreign trade agenda remains in focus
News·
Morning in New York: foreign trade agenda remains in focus
Sales of the drug Wegovy increased by 67%. Will this convince Novo Nordisk investors?
News·
Sales of the drug Wegovy increased by 67%. Will this convince Novo Nordisk investors?
UBS no longer advises buying shares in the maker of Ozempic. Is it inferior to a competitor?
News·
UBS no longer advises buying shares in the maker of Ozempic. Is it inferior to a competitor?
Disney, Palantir and Novo Nordisk reports: what investors need to know this week
News·
Disney, Palantir and Novo Nordisk reports: what investors need to know this week
Pharma stocks plummet after Trumps demand for price cuts. Should we be worried?
News·
Pharma stocks plummet after Trump's demand for price cuts. Should we be worried?
Novo Nordisk shares are having their worst day in almost 40 years. The company downgraded its outlook again
News·
Novo Nordisk shares are having their worst day in almost 40 years. The company downgraded its outlook again
Oral weight-loss drugmaker Viking reports widening loss in 2Q, guides for higher R&D
Small Caps·
Oral weight-loss drugmaker Viking reports widening loss in 2Q, guides for higher R&D
The end of nuclear winter and tens of percent growth: how China is growing its pharma giants
Review·
The end of nuclear winter and tens of percent growth: how China is growing its pharma giants
Business in the age of Ozempic: who will benefit from the growing popularity of weight loss drugs
Review·
Business in the age of Ozempic: who will benefit from the growing popularity of weight loss drugs
Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases
Small Caps·
Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases
Load more